Chemaphor Inc.: Interest in Oximunol (TM) Chewable Tablets Strong at Ontario Association of Veterinary Technicians Conference
05 March 2011 - 1:00AM
Marketwired
Chemaphor Inc.(TSX VENTURE: CFR) At the recent Ontario Association
of Veterinary Technicians (OAVT) Conference held in London,
Ontario, about 1000 veterinary technicians were introduced to
Avivagen Animal Health Inc. ("Avivagen") and its new products
Oximunol™ Chewable Tablets and VetStem RC Regenerative Cell
Therapy.
"Our participation in this tradeshow produced hundreds of leads
from veterinary technicians interested in Oximunol™ Chewable
Tablets and VetStem RC Regenerative Cell Therapy," said Kira
Andersen, sales representative with Avivagen Animal Health. "We are
going to be very busy following up with all those clinics in the
coming weeks." About 250 technicians took time to talk at length
with the Avivagen reps and sign up for a free draw for two pet
baskets and a number of 50-day bottles of Oximunol™ Chewable
Tablets to try on their own dogs.
"I am most definitely interested in trying Oximunol™ Chewable
Tablets on my 15 year old Jack Russell after learning about it,"
said Nicole Swartzentruber, a registered veterinary technician with
Embro Veterinary Services in Embro, Ontario. "If I see results in
his mobility and overall health, I will definitely tell the
veterinarians I work with about it."
The OAVT Conference was the first of numerous key tradeshows
planned this year for Avivagen. Other major tradeshows booked
include the American Animal Hospital Association/Ontario Veterinary
Medical Association Conference in Toronto, ON, the Association des
medecins veterinaries du Quebec, in Saint-Hyacinthe, QC, the
Canadian Veterinary Medical Association Conference in Halifax, NS,
the Animal Health Technologists Association of British Columbia
Conference in Kamloops, BC and the CanWest Veterinary Conference in
Banff, AB.
Oximunol™ Chewable Tablets contain OxC-beta, a fully oxidized
form of ss-carotene, that is made up of compounds occurring
naturally in the plant world. These compounds offer significant
health benefits to dogs in a palatable, chewable daily tablet.
Canadian clinical trials have shown a statistically significant
improvement in coat quality, including a reduction of shedding.
Oximunol™ Chewable Tablets also help dogs enjoy activity more and
help optimize normal gastrointestinal and general health,
especially in older and less active dogs.
VetStem RC Regenerative Cell Therapy is scientifically proven
for treatment of arthritic conditions, and joint and ligament
injuries in dogs, cats and horses. The therapy uses regenerative
cells derived from an animal's own adipose tissue. A small amount
of fat tissue is extracted by the patient's veterinarian, and then
couriered to Avivagen Animal Health's new, state-of-the-art,
Canadian laboratory facility in Charlottetown, PEI. The cells are
processed and counted, following stringent sterility and quality
assurance guidelines. The doses required for immediate treatment
are then returned to the veterinarian for injection into the
patient, often within 48 hours of extraction. Extra doses are
stored by Avivagen Animal Health for future treatments.
Avivagen is a new Canadian company dedicated to improving the
quality of life of animals through science-based, natural health
products proven in clinical trials and sold exclusively through
veterinarians. Avivagen is a subsidiary of Chemaphor Inc., a
Canadian company dedicated to the research and development of
science-based, natural products for people and animals. VetStem RC
Regenerative Cell Therapy has been exclusively licensed by Avivagen
for the Canadian animal health market from Vet-Stem (USA).
Chemaphor is a publicly traded company listed on the (TSX
VENTURE: CFR).
™ Trademark of Chemaphor Inc. VetStem RC Regenerative Cell
Therapy is licensed from Vet-Stem, Inc.
Forward Looking Statements
This news release includes certain forward-looking statements
that are based upon current expectations, which involve risks and
uncertainties associated with the business of Chemaphor Inc. and
Avivagen Animal Health Inc. and the environment in which their
respective businesses operate. Any statements contained herein that
are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions
"will", "anticipate", "believe", "plan", "estimate", "expect",
"intend", and similar expressions. The forward-looking statements
reflect the current expectations of Chemaphor Inc. and Avivagen
Animal Health Inc. regarding future results or events. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ
materially from current expectations. Chemaphor assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those reflected in
the forward-looking statements. The results of treatment described
above are based on historical results. Different animals may
experience different results from the treatments described above.
Anyone interested in the treatments described above should discuss
the potential benefits and risks of such treatments with their
veterinarian.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Avivagen Animal Health Inc. David Hankinson CEO
902-825-9270 Chemaphor Inc. Graham Burton, PhD President and
Co-Founder 613-990-0969 Investor Relations: Evolution Group Inc.
Sylvain Archambault 514-448-4887 / Toll free: 866-703-4887
s.archambault@evolutiongrp.com www.evolutiongrp.com
Chemaphor Inc. (TSXV:CFR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chemaphor Inc. (TSXV:CFR)
Historical Stock Chart
From Jul 2023 to Jul 2024